Jaime Merchan, M.D.
- Associate Professor
Dr. Merchan’s research interest is in the development of novel strategies to overcome resistance to antiangiogenic agents, using syngeneic and xenograft cancer models of renal cell, breast and colon cancer. Among the strategies he is investigating are the use of novel recombinant oncolytic viral agents re-designed to target tumor stromal components, and dual targeting (stromal-vascular and tumor cells). This project is currently funded by the NIH. In addition, he is investigating the effects of metabolic targeting of tumor endothelium, as a strategy to overcome resistance mechanisms. Dr. Merchan is the current Director of the Phase I program at the University of Miami, Sylvester Comprehensive Cancer Center, and has a track record of moving projects from bench to bedside, with translational projects that led to innovative phase I trials in renal cell carcinoma and solid tumor patients.